American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer Review uri icon

Overview

MeSH Major

  • Biomarkers, Tumor
  • Breast Neoplasms

abstract

  • Thirteen categories of breast tumor markers were considered, six of which were new for the guideline. The following categories showed evidence of clinical utility and were recommended for use in practice: CA 15-3, CA 27.29, carcinoembryonic antigen, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, urokinase plasminogen activator, plasminogen activator inhibitor 1, and certain multiparameter gene expression assays. Not all applications for these markers were supported, however. The following categories demonstrated insufficient evidence to support routine use in clinical practice: DNA/ploidy by flow cytometry, p53, cathepsin D, cyclin E, proteomics, certain multiparameter assays, detection of bone marrow micrometastases, and circulating tumor cells.

publication date

  • November 20, 2007

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.14.2364

PubMed ID

  • 17954709

Additional Document Info

start page

  • 5287

end page

  • 312

volume

  • 25

number

  • 33